Phase I and pharmacologic study of irinotecan administered as a 96-hour infusion weekly to adult cancer patients

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 659-667

  Takimoto, Chris H ^a   Morrison, Geraldine ^a   Harold, Nancy ^a   Quinn, Mary ^a   Monahan, Brian P ^a   Band, Roger A ^a   Cottrell, Jeff ^a   Guemei, Aida ^a   Llorens, Victor ^a   Hehman, Hilary ^a   Ismail, Abdel Salam ^a   Flemming, Donald ^a   Gosky, David M ^a   Hirota, Haruyo ^a   Berger, Sosamma J ^a   Berger, Nathan A ^a   Chen, Alice P ^a   Shapiro, Jeremy D ^a   Arbuck, Susan G ^a   Wright, John ^a   Hamilton, J Michael ^a   Allegra, Carmen J ^a   Grem, Jean L ^a   more..

^a WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; IRINOTECAN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON TUMOR; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM TUMOR; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0033950287     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.659     Document Type: Article

References (32)

1. Takimoto CH, Arbuck SG: The camptothecins, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy, (ed 2) Philadelphia, PA, Lippincott-Raven, 1996, pp 463-484
2. Hashimoto H, Chatterjee S, Berger NA: Mutagenic activity of topoisomerase I inhibitors. Clin Cancer Res 1:369-376, 1995
3. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996
4. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
5. Conti JA, Kemeny NE, Saltz LB, et al: Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 14:709-715, 1996
6. Rougier P, Bugat R, Douillard JY, et al: Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15:251-260, 1997
7. Gerrits CJ, de Jonge MJ, Schellens JH, et al: Topoisomerase I inhibitors: The relevance of prolonged exposure for present clinical development. Br J Cancer 76:952-962, 1997
8. Houghton PJ, Cheshire PJ, Hallman JD, et al: Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393-403, 1995
9. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
10. Takimoto C, Dahut W, Harold H, et al: A phase I trial of a prolonged infusion of 9-aminocamptothecin (9-AC) in adult patients with solid tumors. Proc Am Soc Clin Oncol 14:471, 1996 (abstr 1554)
11. Creemers GJ, Gerrits CJ, Schellens JH, et al: Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer. J Clin Oncol 14:2540-2545, 1996
12. Danks MK, Marion RC: Comparison of intermittent and continuous exposure to topotecan in medulloblastoma cells. Proc Am Assoc Cancer Res 37:436, 1996 (abstr)
13. Ohe Y, Sasaki Y, Shinkai T, et al: Phase I study and pharmacokinetics of CPT-11 with 5-day continuous infusion. J Natl Cancer Inst 84:972-974, 1992
14. Division of Cancer Treatment: Guidelines for Reporting Adverse Drug Reactions. Bethesda, MD, National Cancer Institute, 1988
15. Abigerges D, Armand JP, Chabot GG, et al: Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86:446-449, 1994
16. Rivory LP, Robert J: Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 661:133-141, 1994
17. Gupta E, Lestingi TM, Mick R, et al: Metabolic fate of irinotecan in humans: Correlation of glucuronidation with diarrhea Cancer Res 54:3723-3725, 1994
18. Gilbaldi M, Perrier D: Pharmacokinetics. New York, NY, Marcel Dekker, Inc, 1982
19. Mick R, Gupta E, Vokes EE, et al: Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: Prediction of biliary index and intestinal toxicity. J Clin Oncol 14:2012-2019, 1996
20. Rothenberg ML, Kuhn JG, Burris HA III, et al: Phase I and pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11:2194-2204, 1993
21. Abigerges D, Chabot GG, Armand JP, et al: Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 13:210-221, 1995
22. Chabot GG, Abigerges D, Catimel G, et al: Population pharmacokinetics and pharmacodynamics of irinotecan (CKT-11) and active metabolite SN-38 during phase I trials. Ann Oncol 6:141-151, 1995
23. Rowinsky EK, Grochow LB, Ettinger DS, et al: Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54:427-436, 1994
24. de Fomi M, Bugat R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994
25. Sasaki Y, Hakusui H, Mizuno S, et al: A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38. Jpn J Cancer Res 86:101-110, 1995
26. Canal P, Gay C, Dezeuze A, et al: Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer: Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 14:2688-2695, 1996
27. Zamboni WC, Stewart CF, Cheshire PJ, et al: Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models. Clin Cancer Res 4:743-753, 1998
28. Haaz MC, Rivory LP, Riche C, et al: The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes: Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol 356:257-262, 1997
29. Tsuji T, Kaneda N, Kado K, et al: CPT-11 converting enzyme from rat serum: Purification and some properties. J Pharmacobio-Dyn 14:341-349, 1991
30. Slatter JG, Su P, Sams JP, et al: Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos 25:1157-1164, 1998
31. Stewart DF, Ma M, Furman WL, et al: Pharmacokinetics of irinotecan and its active metabolite SN-38 in children with recurrent solid tumors after protracted low dose IV irinotecan. Proc Am Soc Clin Oncol 17:186a, 1998 (abstr 715)
32. Sasaki Y, Yoshida Y, Sudoh K, et al: Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11. Jpn J Cancer Res 86:111-116, 1995